Pooled analysis of randomized trials on the effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction (EF) showed the effects were clinically meaningful and similar in patients with EF below 65% but were attenuated in patients with EF above 65%.

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction – European Heart Journal

Commentary on Twitter

Effect of empagliflozin on heart failure hospitalizations: news from the pooled analysis on both the EMPEROR-Reduced and EMPEROR-Preserved trials! #empaglifozin #heart #failure #hospitalization#ehj #cardiotwitter@escardio @ESC_Journals https://t.co/W6FuYbwVzx pic.twitter.com/5qLXDVaC89

— EHJ Editor-in-Chief (@ehj_ed) December 11, 2021